Insmed Incorporated — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. Although the request metadata refers to 2022 Q4, this filing reports full-year results, not standalone fourth-quarter results. Insmed is a commercial-stage biopharmaceutical company whose only approved product is ARIKAYCE; its pipeline includes brensocatib, TPIP and early-stage research programs.
Key financial results
| Metric | FY2022 | FY2021 | Change |
|---|---|---|---|
| Net product revenue | $245.4 million | $188.5 million | Up 30.2% |
| Operating loss | $457.3 million | $375.1 million | Loss widened |
| Net loss | $481.5 million | $434.7 million | Loss widened 10.8% |
| Net loss per share, diluted | $3.91 | $3.88 | Loss per share increased |
| Net cash used in operating activities | $400.4 million | $363.3 million | Cash use increased |
| Cash and cash equivalents | $1,074.0 million | $716.8 million | Up $357.3 million |
| Marketable securities | $74.2 million | $50.0 million | Up $24.2 million |
| Working capital | $1,083.1 million | $701.9 million | Up $381.2 million |
Cost of product revenue, excluding intangible amortization, was $55.1 million, or 22.5% of revenue, compared with $44.2 million, or 23.4%, in 2021. On that basis, gross profit was approximately $190.2 million and gross margin approximately 77.5%, versus $144.3 million and 76.6% in 2021. These figures exclude intangible amortization.
Research and development expense rose 45.7% to $397.5 million, primarily reflecting manufacturing and clinical-trial spending, including ASPEN and the ARIKAYCE frontline program. Selling, general and administrative expense rose 13.5% to $265.8 million, including higher headcount and commercial launch costs. The company reported an accumulated deficit of $2.7 billion and expects continued operating losses.
Revenue and material changes
- US ARIKAYCE revenue was $186.0 million, up 16.6%; Japan revenue was $56.5 million, up 253.0%; Europe and rest-of-world revenue was $2.9 million, down 77.9%.
- Revenue growth came principally from the US and Japan. Europe revenue was affected by market access and reimbursement developments, including the French ATU price settlement.
- The French settlement reduced FY2022 revenue by approximately $7.5 million, including $5.8 million attributable to periods before 2022.
- Operating loss included a $20.8 million gain from changes in the fair value of acquisition-related deferred and contingent consideration. Interest expense declined to $26.4 million from $40.5 million, mainly because adoption of ASU 2020-06 ended accretion of the convertible-note debt discount; this was partly offset by new financing costs.
Cash, financing and debt
Financing activities provided $793.3 million in 2022, principally from a $350 million senior secured term loan, $150 million royalty financing and equity issuance. The October common-stock offering generated $258.8 million net proceeds; the ATM program generated a further $33.4 million net proceeds during the year. Investing activities used $34.6 million.
At year-end, long-term debt had a carrying value of $1,125.3 million, comprising $800 million face value of convertible notes and the term loan, net of applicable issuance costs and accounting adjustments. The separately reported royalty-financing liability was $148.0 million. The term loan matures in October 2027, bears interest at SOFR plus 7.75% subject to a 2.5% SOFR floor, and has scheduled repayments beginning in 2026, subject to possible extension conditions. The royalty financing requires payments tied to ARIKAYCE sales and, if approved, brensocatib sales; total payments are capped at 1.8x or, under certain conditions, 1.9x the $150 million purchase price.
Management said available cash and marketable securities were expected to fund operations for at least the next 12 months, while noting that additional capital may be needed. The company has no cash dividend policy and expects to retain any earnings for operations and development.
Outlook, risks and notable items
- ARIKAYCE: US approval remains accelerated and conditional on the post-marketing confirmatory program. Insmed anticipated ARISE topline data in Q3 2023 and ENCORE enrollment completion by year-end 2023; successful ENCORE results are necessary for full US approval. The filing describes risks of trial delay or failure, potential approval withdrawal, safety concerns, reimbursement pressure and dependence on concentrated customers and third-party manufacturers.
- Brensocatib: The Phase 3 ASPEN trial was expected to complete enrollment in Q1 2023, with topline data anticipated in Q2 2024. The company planned Phase 2 development in CRSsNP and commercial-readiness work, contingent on approval. Efficacy, safety, enrollment and regulatory outcomes remain uncertain.
- TPIP: Phase 2 studies in PH-ILD and PAH were ongoing. Interim blinded PH-ILD safety and tolerability information was anticipated in the second half of 2023, with topline results expected in the first half of 2024.
- Spending and supply: Management expected R&D expense to increase in 2023. ARIKAYCE supply depends on a limited number of contract manufacturers and PARI is the sole Lamira nebulizer supplier. Patheon’s planned additional manufacturing capacity depended on completion of technology transfer and construction.
- Pricing and reimbursement: A one-time prospective ARIKAYCE price decrease in Japan, estimated at high-single-digit to low-double-digit percentages, was anticipated in 2023. The filing also notes unresolved or changing reimbursement access in certain European markets and the potential effects of US drug-pricing reforms.
- Financing and dilution: The company has substantial cash burn, significant debt and covenants restricting certain actions. Convertible notes and equity issuance may dilute shareholders; royalty payments also reduce future product proceeds.
- Other unusual matters: Insmed adopted ASU 2020-06 in 2022, recording an opening balance-sheet adjustment that reduced shareholders’ equity by approximately $214.4 million; this was an accounting transition, not a current-year operating cash outflow. A new ERP system went live in Q3 2022. Management and the auditor reported effective internal controls at year-end; the auditor issued unqualified opinions on the financial statements and internal control.
Most important facts for investors to verify
- Current ARIKAYCE sales trajectory, customer concentration, reimbursement access and the financial effect of the French settlement and Japan price reduction.
- ARISE and ENCORE progress, endpoint validation, enrollment, confirmatory results and the FDA’s requirements and timing for full approval.
- ASPEN enrollment and results, and whether pipeline milestones and anticipated timelines remain achievable.
- Cash runway against operating cash use, planned R&D and commercial spending, and whether further financing is likely.
- Debt-service terms, covenant compliance, SOFR exposure and royalty-financing payments as ARIKAYCE sales evolve.
- Manufacturing capacity and reliability, including Patheon’s readiness and continued dependence on Resilience and PARI.